Lasofoxifene in combination with abemaciclib

Phase 3Small molecule

Lasofoxifene in combination with abemaciclib is one of 84 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Metastatic Breast CancerRecruiting

Breast CancerPhase 3

Active, not recruiting

Sickle Cell DiseasePhase 3

Active, not recruiting

Metastatic Breast CancerPhase 3

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lasofoxifene in combination with abemaciclib

SSermonix Pharmaceuticals Inc.

Phase 3

2 2

Adriamycin

GGynecologic Oncology Group

Preclinical

87 3

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Chirocaine

PPurdue Pharma LP

Preclinical

1 6

Vfend

PPrism Pharmaceuticals

Preclinical

—7

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 10

Dextromethorphan Hydrobromide

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 3Recruiting

Sickle Cell Disease

NCT04432454

Q2 2028

Phase 3Recruiting

Metastatic Breast Cancer

NCT05696626

Clinical

Trials by Indication[1]

Metastatic Breast Cancer1 trial

An Open Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of the Combination of Lasofoxifene and Abemaciclib to the Combination of Fulvestrant and Abemaciclib for the Treatment of Pre- and Postmenopausal Women and Men With Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting·SSermonix Pharmaceuticals Inc.·Phase 3·NCT05696626·600 enrolled

Sickle Cell Disease1 trial

RUBY-1: Crovalimab in Sickle Cell Disease

Recruiting· Roche logo

Roche·Phase 3·NCT04432454·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lasofoxifene in combination with abemaciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lasofoxifene in combination with abemaciclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lasofoxifene in combination with abemaciclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sermonix Pharmaceuticals Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSermonix Pharmaceuticals Inc.

Lasofoxifene in combination with abemaciclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

Metastatic Breast Cancer1 trial

Sickle Cell Disease1 trial

References

Drug Info

Quick Facts

Related News